Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010/11 to 2016/17

Pebody, Richard G. and Warburton, Fiona and Andrews, Nick and Sinnathamby, Mary and Yonova, Ivelina and Reynolds, Arlene and Robertson, Chris and Cottrell, Simon and Sartaj, Muhammad and Gunson, Rory and Donati, Matthew and Moore, Catherine and Ellis, Joanna and de Lusignan, Simon and McMenamin, Jim and Zambon, Maria (2018) Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010/11 to 2016/17. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 23 (39). ISSN 1560-7917 (https://doi.org/10.2807/1560-7917.ES.2018.23.39.18...)

[thumbnail of Pebody-etal-Eurosurv-2018-Uptake-and-effectiveness-of-influenza-vaccine-in-those-aged-65-years]
Preview
 Text. Filename: Pebody_etal_Eurosurv_2018_Uptake_and_effectiveness_of_influenza_vaccine_in_those_aged_65_years.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (259kB)| Preview

Abstract

Background: In 2016/17, seasonal influenza vaccine was less effective in those aged 65 years and older in the United Kingdom. We describe the uptake, influenza-associated mortality and adjusted vaccine effectiveness (aVE) in this age group over influenza seasons 2010/11-2016/17. Methods: Vaccine uptake in 2016/17 and five previous seasons were measured using a sentinel general practitioners cohort in England; the test-negative case-control design was used to estimate pooled aVE by subtype and age group against laboratory-confirmed influenza in primary care from 2010-2017. Results: Vaccine uptake was 64% in 65-69-year-olds, 74% in 70-74-year-olds and 80% in those aged 75 and older. Overall aVE was 32.5% (95% CI: 11.6 to 48.5); aVE by sub-type was 60.8% (95% CI: 33.9 to 76.7) and 50.0% (95% CI: 21.6 to 68.1) against influenza A(H1N1)pdm09 and influenza B, respectively, but only 5.6% (95% CI: - 39.2 to 35.9) against A(H3N2). Against all laboratory-confirmed influenza aVE was 45.2% (95% CI: 25.1 to 60.0) in 65-74 year olds; - 26.2% (95% CI: - 149.3 to 36.0) in 75-84 year olds and - 3.2% (95% CI: - 237.8 to 68.5) in those aged 85 years and older. Influenza-attributable mortality was highest in seasons dominated by A(H3N2). Conclusions: Vaccine uptake with non-adjuvanted, normal-dose vaccines remained high, with evidence of effectiveness against influenza A(H1N1)pdm09 and B, though poor against A(H3N2), particularly in those aged 75 years and older. Forthcoming availability of newly licensed vaccines with wider use of antivirals can potentially further improve prevention and control of influenza in this group.

CORE (COnnecting REpositories)